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Background. The common symptoms of malaria reduce the specificity of clinical diagnosis. Presumptive treatment is conventional
but can lead to overdiagnosis of malaria, delay of appropriate treatment, overprescription of antimalarials, and drug resistance.
Routine use of diagnostic tests can address many of these concerns. Though treatment is often procured from retailers, there is
low availability of rapid diagnostic tests for malaria (MRDTs), a simple, inexpensive, and accurate diagnostic solution. We know
little about the challenges to expanding access to diagnostics through these outlets. Methods. To understand the perceptions of
the benefits and challenges to selling rapid diagnostic tests for malaria, we conducted focus group discussions with antimalarial
retailers who serve the residents of the Webuye Health and Demographic Surveillance Site in western Kenya. Results. Medicine
retailers perceived MRDTs to be beneficial to their customers and businesses but also included cost, fear of the tests, risks of self-
treatment, and regulatory concerns among the challenges to using and selling MRDTs. Conclusion. MRDTs represent a viable
approach to increase access to malaria diagnostic testing. Medicine retailers are eager for MRDTs to be made available to them.
However, certain challenges remain to implementation in retail outlets and should be addressed in advance.
1. Background
Malaria contributes significantly to the global burden of
disease, causing an estimated 0.5 to 2.5 million deaths each
year [1]. To reduce the disease burden, international orga-
nizations advocate treatment for malaria to be administered
within 24 hours of the first symptoms of the disease [2].
However, several signs and symptoms associatedwithmalaria
are shared by a host of other diseases, such as influenza
and pneumonia [3]. As a result, clinical diagnosis has poor
specificity for malaria [4], often resulting in overdiagnosis
of malaria, overprescription of costly antimalarials [5], and
underdiagnosis or delayed treatment of the true cause of fever
[3, 6].
Improving access to accurate parasitological diagnosis is
now of critical concern for malarial control [7]. Microscopic
examination of stained blood films remains the gold standard
for diagnosing malaria, but microscopy requires trained lab-
oratory staff, costly equipment, a constant supply of reagents,
and quality control and supervisory systems [8, 9]. Compared
to microscopic testing, rapid diagnostic tests for malaria
(MRDTs) are easy to use, do not require any specialized
equipment, and are relatively inexpensive, with a retail price
of between $0.58 and $1.15 [10, 11].
Several studies have shown that implementation of
MRDTs in health facilities can reduce overprescription of
antimalarials [8, 12], while supporting appropriate treatment
for those with positive test results. However, health facilities
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are not the only source of treatment for febrile illness, or even
themain source inmany settings. Across sub-Saharan Africa,
private for-profit medicine outlets account for between 33
and 95% of the market share of antimalarial sales volume
[11]. In Kenya, the private for-profit market share is between
50 and 80%, and medicines purchased at retail drug outlets
were the first or only treatment for 34–42% of childhood
fevers [13]. However, a recent study showed that in an area of
relatively highmalaria endemicity, only 56%of clients seeking
antimalarials in the retail sector tested positive for malaria
[14]. Improving targeting of ACTs to patients with malaria
is likely to require expanding access to diagnostics through
drug outlets such as retail shops, chemists, and pharmacies,
where treatment for febrile illness is often first sought [15, 16].
Retail drug shops have limited capacity to offer micro-
scopic testing (MST) for malaria [2, 11, 17]. This is in part
because the Kenya Pharmacy and Poisons Board places
certain requirements on shops that offer diagnostic services
including requiring that specifically trained staff conduct all
diagnostic tests. The board also requires that all retail drug
outlets be registered with the board, that the operator of the
outlet be licensed by the board, and that certain medicines be
dispensed under the supervision of a certified pharmacist or
pharmaceutical technologist [18]. In reality, very few retailers
meet these requirements and therefore very few are formally
registered.
The artemisinin combination therapy (ACT), artemether-
lumefantrine (AL), is the first-line antimalarial in Kenya and
is designated as a prescription-only medicine, although it is
readily available over the counter with a prescription. Since
2010, the Kenyan National Malaria Treatment Guidelines
dictate that all suspected malaria cases should receive par-
asitological confirmation before treatment with AL, but in
practice, availability of diagnosis is restricted to a fraction of
public health facilities and is practically nonexistent in the
retail sector.
Kenya participated in theGlobal Fund’sACT subsidy pro-
gramme, theAffordableMedicines Facility-malaria (AMFm),
since 2010, leading to substantial falls in the price of AL in
the private sector [19, 20] and unofficially legitimizing over-
the-counter sales of AL. The Global Fund has now indicated
that the transition to the next phase of AMFm will include
the option to usemoney fromGlobal Fund grants to subsidize
MRDTs in the retail sector [21]. Kenyawill nowhave to decide
whether to permit sale of MRDTs in the retail sector given
the success of AMFm in order to reach the large number of
patients who currently purchase AL over the counter without
a diagnostic test.
In summary, in Kenya, as in much of sub-Saharan Africa,
medicine retailers have an important role in the clinical
diagnosis and treatment for fevers. MRDTs are a simple and
affordable alternative that could be used effectively in retail
drug outlets without requiring capital investment and spe-
cialized staff, and implementing MRDTs in the private retail
sector could considerably improve the targeting of ACTs.
Despite the reported success ofMRDT implementation in the
public health sector, very little is known about implementa-
tion in the private sector [17, 22–24]. Understanding the per-
ceptions of medicine retailers would be critical to successful
implementation of MRDTs in this environment, particularly
as Kenya is deciding whether to legalize and/or subsidize
MRDTs in the retail sector as part of its malaria control
strategy. We therefore conducted a study using focus group
discussionswith retailers in a rural district inKenya to gain an
understanding of their perspectives of the benefits and chal-
lenges to using and selling rapid diagnostic tests for malaria.
2. Methods
2.1. Study Area and Sample. The study was conducted in
the Webuye Health and Demographic Surveillance Site
(WHDSS) in the Bungoma East District of Kenya’s Western
Province. The study area’s location, demographics, economy,
and healthcare system have been described in detail else-
where [25].
The study population included all private for-profit retail
locations that sold antimalarials andwerewithin or accessible
to those living in the WHDSS. General shops that sold
household goods were excluded. Retail outlet locations had
been identified and mapped by recorded GPS coordinates
during prior research [20]. Any new retail locations that had
opened since the last mapping activity were also invited to
participate. Ninety-one outlets were identified during this
canvassing activity.
Using the maps as a guide, discussions were held in loca-
tions as convenient as possible to the retailers in those shops,
taking into consideration road conditions, river barriers, and
natural gathering places such as markets and community
centers (see Figure 1 for the clustering strategy).The resulting
locations included 4 discussions at rural locations (held in
Lugulu, Misikhu, Bukembe, and Milo) and two peri-urban
discussions, both held inWebuye Town at theDSS field office.
2.2. Data Collection. The focus group discussions (FGDs)
were conducted in July 2011 by a female social scientist trained
in FGDmoderation and fluent in both Kiswahili and English.
The discussions began with a brief questionnaire focused on
participant education and health qualification level, previ-
ous experience with malaria diagnosis and treatment, and
knowledge of specific diagnosticmethods. Following this, the
discussion explored experiences with malaria diagnosis and
treatment, retailer relationships with customers, a demon-
stration of a rapid diagnostic test formalaria, and perceptions
of the test, its feasibility, profitability, and potential role in
the diagnostic and treatment process. Specific questions were
asked regarding treatment patterns in retail drug outlets,
and how the introduction of MRDTs might influence these
patterns. Of the 91 outlets identified, 61 participants attended
the focus groups, with a median group size of 10.
The FGD guide and questionnaire were pretested in
Eldoret, Kenya, revised, and translated into Kiswahili. Revi-
sions made following the pilot increased clarity, relevance
and reduced repetition. The moderator was trained on the
implementation of this specific discussion guide as well as on
the study protocol and objectives.
The MRDT selected for the demonstration was the
ICT malaria Pf cassette by ICT Diagnostics, which meets
Malaria Research and Treatment 3
Figure 1:Map of study area including numbered boundaries of each
focus group catchment area.
the recommended selection criteria for malaria rapid diag-
nostic tests as published by the World Health Organization
[26]. A laboratory technician employed by the Webuye
District Hospital performed the demonstration.
2.3. Data Entry and Analysis. Focus group discussions were
recorded with digital audio recorders and translated into
English by the research team. Hand-written notes captured
during the discussions were also translated into English.
Both sources were entered and coded using QSR NVivo 9
software. Initial codes were developed based on the exist-
ing literature. After these data were examined, subsequent
codes were developed from themes that emerged during
data review. Data were coded into these themes and then
analyzed for similarity, frequency, strength, and relationship.
These themes were vetted with the research team, project
collaborators, and local members of theWebuye DSS team to
gainmore insight into the significance of the emerged themes.
A second analysis was then conducted, incorporating these
additional findings, and drawing new comparisons between
the more relevant themes.
2.4. Ethical Considerations. Ethical approval was granted
fromMoi University Institutional Research and Ethics Com-
mittee in Eldoret, Kenya, and the Duke University Insti-
tutional Review Board in Durham, NC, USA. All study
participants were informed of the objectives of the study in
the written invitation as well as prior to participation in the
discussion. Verbal consent was obtained from all participants
in the study. Verbal consent was also obtained from all
participants to voice recordings of the discussion, manual
notation of discussion subject matter, nonverbal behavior,
and environmental content. Study participants received light
refreshments at the close of the discussion, and reimburse-
ment for their travel expenses (∼3.5USD per participant).
3. Results
3.1. Characteristics of Medicine Retailers. More than half the
study population was female (59%) and between the ages
of 21 and 40 (66%). Most participants had received training
in the field of pharmacy (44%) or nursing/midwifery (18%)
with two clinical officers (3%) and one participant without
any formal health training. Most participants reported com-
pleting secondary school (41%), with others reporting some
education above secondary school (39%). However, the level
of education reported did not always align with reported
health training. One clinical officer stated to have received
only a primary school education, and 5 out of 11 pharmacists
and 8 out of 17 nurse/midwives reported no education above
secondary school. Participant characteristics by focus group
are covered in Table 1.
3.2. Perceived Benefits of SellingMRDTs in Retail DrugOutlets.
Though most medicine retailers were not familiar with rapid
diagnostic tests for malaria (84%), after the demonstration,
many of them felt it would be a beneficial product.
“If it can be easily available, it can prevent this
issue of giving patients drugs without knowing
the exact disease because somebody can come to
the shop explaining those symptoms related to
malaria, but if you have the kit, you can test
the patient and confirm there instantly.” (FGD 2,
Webuye)
Several specific benefits to implementing MRDTs in
retail outlets were identified by retailers, including furthering
retailer expertise and reducing malaria incidence in the
area. Four major benefits emerged in the analysis which are
elaborated below: MRDTs may attract more business to drug
outlets,MRDTsmay save time andmoney for both customers
and retailers, they may increase access to malaria diagnostics
and thereby appropriate treatment, and they may increase
customer and retailer confidence in diagnosis and treatment.
3.3. MRDTs May Bring Business to Shops. Retailers antici-
pated that selling MRDTs in their outlets would help them
retain customers that they would have previously referred to
hospitals or laboratories for testing.They felt they could even
bring in new customers by offering diagnostic services, and
that this could improve an outlet’s reputation making them
more attractive than their competitors.
“I think you will also be getting direct patients, not
those who come with prescriptions. You actually
create your own patients. After testing, now you
have your clients. Like me, I will not be referring.
Sometimes you send a client for testing and she/he
goes away. So it’s a benefit.” (FGD 5, Bukembe)
3.4. MRDTs May Save Time and Money. Retailers felt that
selling rapid diagnostic tests in drug outlets would prevent
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Table 1: Focus group participant data from self-administered questionnaire.
Peri-urban Rural
FGD 1 FGD 2 FGD 3 FGD 4 FGD 5 FGD 6 Total % of total
Total participants 5
5
8 10 16
17
61 100
Women 4
2
5 6 7
12
36 59
Men 1
3
3 4 9
5
25 41
Age
Under 20 1
0
0 0 1
0
2 3
21–30 1
4
1 4 2
8
20 33
31–40 0
1
4 3 7
5
20 33
41–50 1
0
1 1 2
2
7 11
Over 50 1
0
1 1 1
0
4 7
Unreported 1 0 1 1 3 2 8 13
Training
Pharmacist 0 1 1 2 3 4 11 18
Pharmacy tech 1 1 0 1 2 0 5 8
Pharmacy asst 1
1
2 0 4
3
11 18
Medical doctor 0
0
0 0 0
0
0 0
Nurse/midwife 1
0
2 3 5
6
17 28
Clinical officer 0
0
0 0 1
1
2 3
Untrained 1
0
0 0 0
0
1 2
Unreported 1 2 3 4 1 3 14 23
Education
Completed primary 0
0
0 0 0
1
1 2
Some secondary 0
0
0 1 1
2
4 7
Completed secondary 4
0
6 3 4
8
25 41
Above secondary 0
3
1 4 11
5
24 39
Unreported 1 2 1 2 0 1 7 11
customers fromneeding to travel to public health facilities for
testing, saving customers the time and cost of travel. Patients
would also be able to save time by avoiding the long queues
and additional costs associated with public health facility
visits.
Retailers perceived that using rapid tests for malaria
would save them money as well, since it is cheaper for
them than microscopy, in terms of equipment price and staff
training. Only 7% of medicine retailers had ever performed
MST in their outlets. Performing microscopic testing can
be challenging for retail drug outlets due to the cost of
equipment, training personnel, and necessary experience to
read slides accurately [27].
ConductingMST is also a laborious and time-consuming
process. The simplicity and ease of use of MRDTs was seen
as a benefit by participants, specifically over microscopic
testing, which may lead to an increase in use of diagnostic
testing by retailers. It was discussed that rapid tests also
deliver a definitive diagnosis quickly, allowing retailers to
serve more customers in less time.
“I think it is a very nice one because now you do
not need to go for a microscope and it’s cheaper.
Themicroscope, themachine is very expensive, but
for this one, if you buy at Ksh.50 ∼USD $0.58, you
can afford Kshs.500∼USD$5.75 per week and test
those clients. Also, everybody can test provided the
instructions are followed well.” (FGD 5, Bukembe)
3.5. MRDTs May Increase Appropriate Treatment and Access
to Malaria Diagnostics. Retailers saw MRDTs as a way to
increase access to malaria diagnostics. Since their outlets
are open more often than public health facilities and outlets
service rural areas with limited access to public facilities,
offering MRDTs in retail locations would increase access to
diagnostics to these communities. They also saw offering
testing in their outlets to be more convenient and less
costly for their customers, also increasing access since this
may encourage more customers to take advantage of testing
services.
Retailers felt that increasing the use ofmalaria diagnostics
would also increase the appropriateness of treatment. Retail-
ers said this was significant to them, and that they felt it was
important to treat patients accurately.
“When you test, it can help you to give the right
drugs to the patient.” (FGD 3, Lugulu)
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“What matters most is the test, to know exactly
what you are treating. That’s the most important
thing.” (FGD 3, Lugulu)
3.6. MRDTs May Increase Confidence in Diagnosis and Treat-
ment. Retailers felt that having access to definitive diagnosis
could increase a customer’s confidence in the accuracy of
that diagnosis, and in the treatment they receive. They may
be more likely to accept the treatment recommended by the
retailer, or to purchase alternative medications in cases with
a negative test result. Retailers also felt that customers may
have more confidence in MRDTs than in laboratory tests.
“I think the patient will be comfortable because
she/he will just look at the results. Maybe in the
lab, the person may not be able to see the results.”
(FGD 1, Webuye)
Retailers also appreciated avoiding uncertainty in their
diagnoses by using the tests.
“I think there will be no more guess work. I will be
doing something I am sure of and dispensing the
right drug.” (FGD 5, Bukembe)
3.7. Perceived Challenges to Selling MRDTs in Retail Drug
Outlets. Medicine retailers recognized several challenges to
implementing and selling MRDTs in their outlets. Of the
concerns mentioned, four challenges were mentioned most
frequently and with the most emphasis. They include the
costs of MRDTs, customer fears associated with diagnostic
testing, the risk of customer self-treatment with the tests, and
regulatory problems that providing diagnostic services might
cause for retail drug outlets.
3.7.1. The Cost of MRDTs May Dissuade Customers. Retailers
perceived that customers may not be able to afford any
additional cost beyond that of treatment. There were also
concerns that some customers would believe retailers were
selling tests only to make more money, and that the cost is
being manipulated by retailers to increase profits. It was felt
that these issues could be overcome if customers are educated
on the use of MRDTs, and the importance of diagnostic
testing.
“Some customers will think we want to squeeze
out some money from them. Some will even say,
mymoney wasmeant for buying drugs not testing.
This is especially so among those who do not know.
So, a lot of talking and convincing is needed. If
good health is given, they will understand.” (FGD
5, Bukembe)
3.7.2. Customers May Fear MRDTs. Some medicine retailers
held the perception that some of their customers may be
afraid of getting tested, associating the finger prick necessary
for an MRDT with a needle injection. Others felt that their
customers may associate the malaria test with an HIV test.
Retailers also said that if they started testing with MRDTs,
their customers might think the government is secretly
testing for HIV.
“There might be a challenge somewhere, in local
areas, we have some people who fear these
HIV/AIDS tests, so they might think that now the
government is involved in testing malaria but in
a real sense they are testing HIV/AIDS.” (FGD 6,
Milo)
3.7.3. MRDTs May Lead to Self-Medication and Reduce Busi-
ness in Retail Drug Outlets. Several retailers expressed strong
opinions against selling rapid tests directly to customers to
perform themselves at home. One of these concerns was that
customers may test at home and not use the tests correctly,
which could lead to incorrect results, but customersmay treat
themselves at home according to these results. There were
fears that this could lead to misdiagnosis or underdiagnosis,
and mismanagement of undetected diseases. There were also
concerns that testing and treating at home removes the
opportunity for the shop worker to sell a nonmalaria drug.
“RDTs should not be sold to customers because
we will have self-medication. Someone could be
suffering from something else, and someone may
end thinking she/he has been bewitched and
maybe it could be another illness so, strictly, RDTs
should not be sold to customers.” (FGD 1,Webuye)
MRDTs do not indicate the severity of malaria infection,
and several retailers worried that this may bring harm to
children.
“Like for me, I think it should not be used in
children because they are very delicate. Maybe the
child has severe malaria and the RDT does not
show the severity. So we shall lose our babies.”
(FGD 1, Webuye)
There were also concerns that self-testing may cause
outlets to lose business.
“. . .some customers are very funny. They may just
come and buy and go, because it has somemanual
inside, so they will start testing at home. . .They
can make our customers disappear.” (FGD 4,
Misikhu)
3.7.4. MRDTs May Create Regulatory Problems for Retail
Drug Shops. Medicine retailers expressed concerns that the
regulatory bodies overseeing pharmacies and chemists would
not allow them to carry out testing in their outlets.Therewere
also concerns that carryingMRDTswould bring the attention
of the regulatory board, especially on those locations that are
unregistered, and may even require outlets to hire more staff,
bringing additional cost to the owners if they wish to conduct
testing.
“In my case, if I carry out such a diagnostic test,
I must have a lab technician, and in fact, I am
supposed to register the premises. Because if I am
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found by the P.H.O. public health officer, they can
really harass me.” (FGD 4, Misikhu)
Some retailers, particularly those that are near public
health facilities, felt these facilities may prevent the outlets
from performing malaria testing.
“Personally, my shop is located near a dispensary
which has got no laboratory. If they get to know
that I am now performing RDTs for malaria, they
will even threaten to closemy shop.” (FGD 6,Milo)
3.7.5. Acceptance and Adherence. Retailers perceived chal-
lenges regarding customer acceptance of and adherence to
test results, particularly if results are not in agreement with
the customer’s desired outcome. They felt that customers
who expected a positive result but tested negative for malaria
would likely demand antimalarials anyway. This was seen as
a particular problem with clients, often mothers with sick
children, refusing an alternative diagnosis and even conclud-
ing witchcraft was causing the illness.
“The mother won’t accept the results. . .some will
think of supernatural things. . .like bones, that is,
witchcraft. How can the child be sick and there’s
no malaria?” (FGD 3, Lugulu)
Participants also anticipated customer resistance in cases
with positive test results when the patient does not believe
they have malaria.
“in a chemist, some patients are very rude. They
will tell you ‘I do not have malaria’ irrespective
of the test. ‘How do you give me antimalarials?”’
(FGD 1, Webuye)
Customer resistance to adhering to a test result may put
pressure on retailers, making it difficult for them to adhere to
results in terms of dispensing appropriate medication as well.
However, they did not report seeing the loss of a drug sale as
a motive to not adhere to test results. Some said they would
dispense antimalarials anyway, and yet others stated that they
would put a higher priority on treating their customers well
than making a sale, presenting motivations outside of profit
maximization as influences on their behavior.
“To me actually, even if it is business, it is better
you heal somebody than gettingmoney for its sake.
So to me, I do not see any problems withholding
the wrong drugs, so I better treat the patients, not
just get money from somebody.” (FGD 3, Lugulu)
There remained concerns regarding adhering to test
results if a retailer feels the test was inaccurate. There were
cases cited in which retailers believed a test would not detect
malaria, and that in those cases, retailers would not dispense
according to test results.
“Sometimes they test for malaria but it may not
show up, but they could be having malaria.” (FGD
1, Webuye)
4. Discussion
This study explored drug retailer perceptions of the chal-
lenges and benefits to using and selling MRDTs in their
shops. Retail medicine outlets are an important source of
symptomatic diagnosis and treatment for febrile illness.
Self-medication with drugs purchased at retail outlets is a
common practice [8, 13, 16], and medicine retailers have
an important role in the diagnosis and treatment of their
customers [23, 25]. There is increasing interest in improving
treatment for malaria through the private sector, as exempli-
fied by implementation of the global ACT subsidy through
AMFm in 7 countries, including Kenya.The AMFm program
expanded access to affordable and effective antimalarials [19]
but raised questions about overtreatment of fevers with over-
the-counter ACTs [28, 29]. With the high volume of clients
seeking antimalarials in the retail sector, it is important to
increase access to inexpensive and effective diagnostic testing
services to reduce the delay in treating the true cases of febrile
illness, and to limit the overprescription of antimalarials.
While in Africa the expansion of malaria diagnosis in
the retail sector has been limited to date to small-scale pilot
projects, efforts to increase access to and quality of malaria
diagnosis and treatment in the retail sector at a national
scale have been underway in Cambodia since 2000. However,
despite extensive marketing and training efforts, availability
of MRDTs in retail shops remained suboptimal; 49% of
shops stocked MRDTS in 2007 but only 21% of patients with
recent malaria symptoms were tested [30]. Lessons learned
from the Cambodian experience included the importance of
conducting qualitative assessments to understandhow imple-
mentation should be designed and improved.The researchers
also underscore the importance of identifying both financial
and nonfinancial barriers to using and sellingMRDTs, and to
address these barriers before implementation.
There are very few reports of qualitative studies exploring
the readiness of retail drug outlets to take up MRDTs, and all
those available were conducted in Uganda. One such study
[23] noted similar findings: most drug retailers were not
previously familiar with MRDTs, but after the explanation
or demonstration of the product, they felt it would be useful
to them and beneficial to sell in their shops. Retailers in
both studies felt that MRDTs could increase confidence in
a malaria diagnosis and treatment, bring business to their
shops, and improve their reputation as medicine retailers.
Both studies’ findings underscore the potential for MRDTs to
be accepted in the retail environment, and to have a positive
impact on diagnostic access. This is found to be an untapped
area of possibility, as most medicine retailers were unfamiliar
with rapid diagnostic tests.
Focus group participants also anticipated concerns of
their clients. Similar to the Ugandan study by Mbonye and
colleagues [24], shop workers in Webuye expressed concern
that clients may refuse to use MRDTs out of fear of being
tested for HIV. We found that retailers held perceptions that
their customers may not accept a nonmalaria diagnosis or
may turn to witchcraft or other spiritual explanations for
illness that was not caused by malaria. These concerns high-
light the importance of community education and awareness
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to reducemisconceptions about the function and use of rapid
diagnostic tests for malaria as well as education regarding
alternative causes of fever that are symptomatically similar to
malaria.
Adherence to the results of a rapid test formalaria, partic-
ularly a negative result, remains a concern given the findings
of recent implementation studies in health facilities. One
such study in public dispensaries in Tanzania [8] showed
that health workers perceived MRDTs to be quick, easy to
use, enhance appropriate treatment, increase confidence in
diagnoses, and unanimously trusted by dispensary providers.
However, theMRDTresults did not always influence provider
behavior appropriately, and often antimalarials were pre-
scribed to customers with a negative MRDT; at the start of
the implementation, roughly 30% of children who were given
antimalarials had a negative test. Similar results were seen
in Uganda [12] where 35% of those who tested negative by
MRDT in a health facility still received an antimalarial.
In a retail outlet, where healthcare consumers are not
patients but are clients, adherence to the test result may
be more influenced by the preferences of the customer and
the financial incentives faced by providers. Customers may
not accept test results and may demand antimalarials. Shop
workers may fear losing business if they do not respond to
customer demands.
Shop workers themselvesmay also reject the results of the
test or fail to offer a test to the customer. Our study found
several shop workers who described scenarios in which they
may not trust test results, potentially leading to an underuti-
lization of the tests. A recent study by Kedenge and colleagues
[31] evaluating the effectiveness of a subsidized antimalarial
intervention in Kenyan retail shops found that shop workers
did not consistently perform certain components of the
intervention such as provision of advice, stating that they
were too busy with other customers. This trend among for-
profit shop workers may limit their ability to accurately and
consistently administer rapid tests to their clients. Educating
and training retailers on the sensitivity and specificity of
the MRDT, building trust in the test results, demonstrating
the negative effects of dispensing antimalarials to someone
sick with another disease, and coaching retailers on how to
respond to a client with a negative drug test can also help
increase implementation of MRDTs and adherence to test
results.
Adherence to the test results is not the only barrier to
safe and correct implementation of MRDTs in retail outlets.
Training must include instruction on blood handling and
safe disposal of used lancets and other materials. Proper
use of the kit, including loading the blood, waiting for
the results, and interpreting the results, has been identified
as occasionally problematic in studies training laypersons
to use MRDTs. However, proper use of MRDTs has been
achieved in community health worker programs [32–35]
demonstrating that these problems are not insurmountable,
but implementation ofMRDTsmay requiremore supervision
and oversight than is currently provided in the retail sector.
The regulatory environment and health system context
were key barriers identified by focus group participants that
need to be addressed prior to implementation. Participants
in Uganda [24] discussed concerns that health workers and
district health officials felt that drug shops were inadequately
supported by the government and often were not included in
education opportunities. The findings from this study point
more to concerns that the regulatory agencies responsible
for regulation of retail drug shops may not approve of
their providing diagnostic services. In a study by Chandler
and colleagues [23], retail drug shops were viewed with
suspicion and assumed to often operate outside the law.
This perception, whether founded or unfounded, can affect
MRDT implementations due either to a restrictive regulatory
environment or a mistrusting clientele. The majority of retail
shops selling AL are unregistered and sell AL illegally over
the counter. Given the restrictive but largely unenforced
regulatory environment in Kenya, implementing MRDTs in
this areamay hold different challenges thanwere experienced
in Cambodia or other regions. Governmental and regulatory
policies are concerns that are shared in both regions, but the
regulatory environments are quite different and should be
addressed locally.
While these focus group discussion findings provide
valuable insight into the perceptions medicine retailers hold
regarding the sale and use of MRDTs, they are limited in that
participants may have shared what they believe is the correct
views, or views expected by study staff, rather than their
actual opinions. Most participants were not familiar with
RDTs and, following the demonstration, their commentsmay
have partly been in response to the novelty of the tests rather
than their expected utility. Pilot implementation studies may
therefore shed additional light on true acceptability ofmalaria
testing in a retail setting.
There was found an inconsistency in the type of health
training and level of education collected by the brief ques-
tionnaire administered before the start of the focus group
discussions. Forty-five percent of participants indicating a
pharmacist training (5/11), and 47% of participants indicating
a nursing or midwifery training (8/17) reported that they did
not have an education above secondary school. Additionally,
two participants reported their level of health-related qualifi-
cation to be that of clinical officer, but one of these reported
that they had only received education through primary
school.However, to hold diploma certificates in these training
areas requires an education above secondary school. This
inconsistency could be explained by either the participants
misunderstanding the question pertaining to health training
or education on the survey or that they self-identify with
a certain health title that comes from holding that occu-
pation, rather than from having formal training. A similar
dichotomy was found in a recent quantitative investigation
that studied a similar population [25]. Following discussions
on this finding with local research team, clinicians, and
public health practitioners familiar with the area, it was their
opinion that medicine retailers, particularly in rural areas,
are referred to by the local community as “pharmacists” or
“nurses” because these are the social roles they fill in the
community, not bearing on whether those individuals hold
official health qualifications in that field. It was conjectured
that these retailers may self-identify in accordance with these
roles.
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Since the study did not collect personal information about
the participants, and did not require advance identification
of participants discussion comments could not be sorted by
gender, training, or type of retail facility. As a result, having
men and women in the same discussions, or high and low
levels of training represented in the same discussion, may
have inhibited some participants from speaking or from shar-
ing truthful answers. This study did not include consumer
perceptions, which could also influence the feasibility of
implementing MRDTs in this environment. Further research
needs to be conducted in this area to ensure that retailers
are acceptable providers of diagnostic services, and that
perceptions consumers have regarding the purchase and use
of MRDTs are well known and accounted for in intervention
planning.
5. Conclusions and Recommendations
Given the established consumer behavior of first seeking
malaria treatment from medicine retailers, and the high
rates of overdiagnosis of malaria, the introduction of MRDTs
in these medicine outlets has the potential to substantially
improve appropriate treatment. Studies have shown that
MRDTs are highly sensitive and specific for malaria, and that
withholding antimalarials in cases with negative tests does
not put children at greater risk for complication or death
[26, 36, 37]. Implementing MRDTs in retail locations is an
important next step in increasing access to much-needed
diagnostic services.
However, this study uncovered potential challenges to
implementation that should be addressed in advance of these
efforts. Addressing retailer concerns regarding community
acceptability by heightening community awareness of the
potential for nonmalaria causes of fever will be critical to
creating an environment wheremedicine retailers can adhere
to MRDT results and withhold antimalarials in cases with
negative tests. Support from local community leaders, chiefs,
and elders, as well as from private health sector consumers,
public health facilities, and regulatory agencies, will assist
in developing a solid foundation for the implementation of
MRDTs.
Pilot studies are now underway exploring the use of
MRDTs in private outlets [38, 39]. Results from such studies
need to be carefully examined to measure the wider impact
of providing testing in drug outlets, and how this provision
relates to or may impact the greater healthcare delivery sys-
tem, the supplier/consumer relationship, treatment-seeking
behavior, and the relationship between the informal and
formal healthcare sectors.
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